Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Veelbelovend proefschrift over verbeteren immuuntherapie bekroond
nov 2023 | Immuuntherapie, Maag-darm-leveroncologie